C96.5 Insurance Policy Changes

ICD-10 C96.5 is officially defined as "Multifocal and unisystemic Langerhans-cell histiocytosis." code C96.5 is referenced in 3 tracked payer policy changes from Blue Cross Blue Shield of North Dakota and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C96.5 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross Blue Shield of North Dakota · Identified Aug 29, 2026High impact
Pharmacy Policies Available Online
Blue Cross Blue Shield of North Dakota revised its Commercial prior authorization medical drug policies with changes effective October 13, 2026, including expanded indications for Casgevy, Keytruda, Opdivo and other products and updated criteria for many others. Effective September 1, 2026, Navitrux was added to the fosaprepitant policy and Cligavyx was added to the fulvestrant policy, each kept at full parity with its reference product, and the cerebral palsy spasticity exclusion was removed from the Xeomin pediatric upper limb indication. Several products also have HCPCS code changes effective January 1, 2027.
Aetna · Identified Oct 1, 2026Medium impact
Pulmonary Hypertension Treatments and Selected Indications of Prostanoids (CPB 0184, reviewed 2026-09-02)
Aetna considers epoprostenol (Flolan, Veletri, or generic epoprostenol injection), iloprost inhalation (Ventavis), treprostinil inhalation (Tyvaso), and treprostinil injection (Remodulin or generic treprostinil injection) medically necessary for pulmonary arterial hypertension (PAH) when the initial approval criteria are met, and for pulmonary hypertension associated with interstitial lung disease (PH-ILD) for Tyvaso only. Aetna considers sotatercept-csrk (Winrevair) medically necessary for PAH in members 18 years of age and older when PAH is confirmed by right heart catheterization and the drug is used as add-on therapy alongside medications from at least two of the listed PAH drug classes. Continuation of these therapies is considered medically necessary for members who receive them through a previously authorized pharmacy or medical benefit and who show disease stability or disease improvement.
Aetna · Identified Aug 14, 2026Medium impact
Pulmonary Hypertension Treatments and Selected Indications of Prostanoids (CPB 0184, reviewed 2025-09-08)
Aetna's commercial policy sets the criteria for epoprostenol (Flolan, Veletri), iloprost inhalation (Ventavis), treprostinil inhalation (Tyvaso) and treprostinil injection (Remodulin) for pulmonary arterial hypertension (PAH, WHO Group 1), with Tyvaso also covered for pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO Group 3) when criteria are met. Sotatercept-csrk (Winrevair) is covered for members 18 years of age and older with PAH when they meet its add-on criteria, and atrial septostomy and balloon pulmonary angioplasty are covered for refractory severe PAH with right heart failure. Aetna considers pulmonary artery hypertension drugs experimental for pulmonary hypertension secondary to asthma, chronic obstructive pulmonary disease, congestive heart failure, ischemic vascular disease or lung resection.

Watch C96.5

Get one email when a payer policy names C96.5, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code C96.5?

There are 3 tracked policy changes affecting code C96.5, including updates from Blue Cross Blue Shield of North Dakota, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code C96.5?

Payers that have issued tracked updates for code C96.5 include: Blue Cross Blue Shield of North Dakota, Aetna.

How do I get notified when code C96.5 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code C96.5. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code C96.5?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Pharmacy Policies Available Online

Pulmonary Hypertension Treatments and Selected Indications of Prostanoids (CPB 0184, reviewed 2026-09-02)

Pulmonary Hypertension Treatments and Selected Indications of Prostanoids (CPB 0184, reviewed 2025-09-08)

What insurance policy changes affect code C96.5?

Which payers have updated policy for code C96.5?

How do I get notified when code C96.5 policy changes?

Why do payers change policies for code C96.5?